Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.465 USD | +4.64% | 0.00% | -43.51% |
Apr. 05 | Archon Capital Management Engages with Apyx Medical Corporation | CI |
Apr. 01 | Stavros G. Vizirgianakis Engages in Discussions with Apyx Medical Corporation | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-43.51% | 48.5M | C | ||
-3.69% | 184B | C+ | ||
-1.51% | 107B | C | ||
-2.73% | 67.52B | A | ||
+1.85% | 50.06B | B- | ||
+9.87% | 45.67B | B- | ||
+3.40% | 41B | B+ | ||
+4.03% | 26.73B | B | ||
+4.33% | 26.47B | A- | ||
+15.23% | 25.05B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- APYX Stock
- Ratings Apyx Medical Corporation